Indivior Announces $175 Mln Accelerated Share Repurchase Agreement; Shares Surge

Indivior Pharmaceuticals announced a $175 million accelerated share repurchase agreement with Barclays under its existing $400 million buyback program. The move signals capital return to shareholders and uses less than half of the authorized repurchase capacity. The announcement is routine but modestly supportive for the stock, with limited broader market impact.

Analysis

Indivior Pharmaceuticals announced a $175 million accelerated share repurchase agreement with Barclays under its existing $400 million buyback program. The move signals capital return to shareholders and uses less than half of the authorized repurchase capacity. The announcement is routine but modestly supportive for the stock, with limited broader market impact.